Mortality rates among inpatients with HF who undergo AF catheter ablation are relatively low. LAAO in elderly patients with atrial fibrillation demonstrates similar efficacy to those seen in younger patients. People with amyloidosis have a significantly higher prevalence of atrial fibrillation. In approximately 50% of patients, pulmonary vein isolation (PVI) successfully treats persistent AFib at one year. Théophile Mohr-Durdez, CEO and co-founder of Volta Medical, talks about streamlining workflows for electrophysiologists. People who quit smoking have a lower risk of atrial fibrillation than people who continue to smoke. The EPIC-CAD trial addresses a crucial question in managing patients with both atrial fibrillation and stable CAD. PVI results in clinically important improvements in both symptom burden and quality of life compared with a placebo. Patients with inflammatory bowel disease have a significantly higher risk of developing atrial fibrillation. Monitoring heart rate and physical activity using a wearable device has clinical value. Both rare and common genetic variation is associated with an increased risk of atrial fibrillation. A recent study found that 73% of patients with ATTR-CA had AF at diagnosis. Radiofrequency-based ablation is highly effective for patients with atrial fibrillation. People who are exposed to even small amounts of secondhand smoke have a greater risk of developing atrial fibrillation. According to a study, more patients with AFib are likely to experience heart failure rather than stroke or heart attack. Treating gum disease soon after catheter ablation to correct atrial fibrillation may lower the risk of recurrence. Adults who drink 2 liters or more of sugary or artificially sweetened drinks per week have a higher risk of AFib. Boston Scientific announced the FDA approval of the FARAPULSE PFA System in the treatment of atrial fibrillation. Stuart Long, CEO of InfoBionic, discusses the overall burden of cardiac arrhythmias and how the MoMe ARC can help address it. The use of ADHD medications may be linked to an increased risk of cardiovascular disease.